search

Gabrielle F. Miller, Ph.D., MPH

Senior Director, HEOR

Gabrielle F. Miller headshot - woman with dark mid-length hair smiling for headshot in a black blazer

Gabrielle Ferro Miller, Ph.D., MPH is a Senior Director, Health Economics and Outcomes Research at Inovalon. She brings extensive expertise in epidemiology, health economics, infectious disease, and chronic disease research, with a strong record of leading complex analytic projects that inform public health policy and program development. Her experience spans diverse data sources including administrative claims, vital records, electronic health records (EHRs), and surveillance data.

Gabrielle has authored more than 60 peer-reviewed publications in leading journals such as the American Journal of Public Health, American Journal of Preventive Medicine, and MMWR. Her research includes COVID-19, infectious disease, chronic conditions, traumatic brain injury, and suicide prevention.

With over a decade of experience in public health research and leadership, Gabrielle previously held several roles at the CDC’s National Center for Injury Prevention and Control. As Associate Chief of Science, she directed scientific activities within the Data Analytics Branch and led multidisciplinary project teams. During the COVID-19 pandemic, she served as Unit Lead for the Community Interventions and Critical Populations Task Force, overseeing analytical teams supporting the national response.

Gabrielle earned her Ph.D. in Food and Resource Economics and her Master of Public Health in Public Health Practice from the University of Florida.

Connect on LinkedIn
Authored Content
RWD & Insights

MASH Real-World Data: Why Fibrosis Stage Is the Variable That Matters

Some diseases are difficult to study using claims alone. MASH is one of the clearest examples. Metabolic dysfunction-associated steatohepatitis (MASH) affects an estimated nine to 15 million U.S. adults. Until March 2024, no treatment had been approved specifically for MASH. The therapeutic landscape now includes two approved therapies, both granted accelerated approval and indicated for the same narrow population: adults with moderate to advanced liver scarring who have not progressed to cirrhosis. Cirrhosis represents the most advanced stage of liver scarring, accompanied by extensive disruption of the liver's structure.

Read More →
Share